Drug Profile
HE 3235
Alternative Names: Apoptone; HE-3235Latest Information Update: 29 Sep 2015
Price :
$50
*
At a glance
- Originator Hollis-Eden Pharmaceuticals
- Developer Harbor Therapeutics
- Class Androstanols; Antineoplastics; Hormonal steroids; Small molecules
- Mechanism of Action Androgen receptor antagonists; Apoptosis stimulants; Raf kinase inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Prostate cancer
Most Recent Events
- 29 Sep 2015 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Late-stage disease, Treatment-experienced) in USA (PO)
- 29 Sep 2015 Discontinued - Preclinical for Breast cancer in USA (PO)
- 28 Feb 2011 Pharmacodynamics data from animal studies in breast cancer released by Harbor BioSciences